Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)

[1]  P. Liu,et al.  Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018) , 2022, Cancer Pathogenesis and Therapy.

[2]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[3]  K. Savage.  Primary mediastinal Large B-cell Lymphoma. , 2021, Blood.

[4]  Yuankai Shi,et al.  The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005–2020): A systematic review , 2021, The Lancet regional health. Western Pacific.

[5]  Z. Ge,et al.  Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002) , 2021, Journal of Hematology & Oncology.

[6]  D. Scott,et al.  Outcome of Primary Mediastinal Large B-cell Lymphoma Using R-CHOP: Impact of a PET Adapted Approach. , 2020, Blood.

[7]  M. Piris,et al.  Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up , 2020, Blood Cancer Journal.

[8]  S. Ansell,et al.  The Immune Landscape and Response to Immune Checkpoint Blockade Therapy in Lymphoma. , 2019, Blood.

[9]  Andrew J. Dunford,et al.  Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade. , 2019, Blood.

[10]  W. Wilson,et al.  End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making , 2018, Haematologica.

[11]  M. Jia,et al.  APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer , 2018, Oncogene.

[12]  J. Brahmer,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.

[13]  Yuankai Shi.  Current status and progress of lymphoma management in China , 2018, International Journal of Hematology.

[14]  Sonali M. Smith,et al.  Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted EPOCH‐R , 2017, British journal of haematology.

[15]  M. Shipp,et al.  Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. , 2017, Blood.

[16]  P. Zinzani,et al.  Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. , 2017, Blood.

[17]  S. Nakamura,et al.  High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma , 2015, Blood Cancer Journal.

[18]  Lauren C. Chong,et al.  Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. , 2015, Cell reports.

[19]  R. Gascoyne,et al.  Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. , 2013, Blood.

[20]  Christian Steidl,et al.  The molecular pathogenesis of primary mediastinal large B-cell lymphoma. , 2011, Blood.

[21]  Steven J. M. Jones,et al.  MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers , 2011, Nature.

[22]  M. Pfreundschuh,et al.  Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[24]  R. Tsang,et al.  Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma , 2008, Leukemia & lymphoma.

[25]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[26]  L. Staudt,et al.  Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.

[27]  R. Gascoyne,et al.  Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.